Literature DB >> 11473206

Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy.

M Ohta1, Y Tokuda, Y Suzuki, M Kubota, H Makuuchi, T Tajima, S Nasu, Y Suzuki, S Yasuda, A Shohtsu.   

Abstract

The purpose of this study was to determine the potential role of positron emission tomography (PET) using 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) for the evaluation of bony metastasis compared with 99Tcm-methylene diphosphonate (99Tcm-MDP) bone scintigraphy in patients with breast cancer. Fifty-one female patients with breast cancer who had PET together with a bone scan within 1 month between September 1994 and March 1997 were included in this study. The median age was 49 years (range 29-79 years). The sensitivity, specificity and accuracy of the bone scan were 77.7%, 80.9% and 80.3%, respectively. On the other hand, for the detection of bone metastases PET had a sensitivity, specificity and accuracy of 77.7%, 97.6% and 94.1%, respectively. In the diagnosis of bony metastasis derived from breast cancer, FDG-PET was statistically superior to bone scintigraphy in its specificity. In conclusion, FDG-PET appears to be a powerful tool not only in the diagnosis of the primary lesion and soft tissue metastasis, but also in the diagnosis of bony metastasis among patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11473206     DOI: 10.1097/00006231-200108000-00005

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  32 in total

1.  Bone scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Morteímans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

2.  FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy.

Authors:  Ora Israel; Anat Goldberg; Alicia Nachtigal; Daniela Militianu; Rachel Bar-Shalom; Zohar Keidar; Ignac Fogelman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-22       Impact factor: 9.236

3.  Managing acrometastases treatment strategy with a case illustration.

Authors:  V Spiteri; A Bibra; N Ashwood; J Cobb
Journal:  Ann R Coll Surg Engl       Date:  2008-10       Impact factor: 1.891

4.  Skeletal metastases: what is the future role for nuclear medicine?

Authors:  Gary J R Cook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11       Impact factor: 9.236

Review 5.  Diagnosis of bone metastases: a meta-analysis comparing ¹⁸FDG PET, CT, MRI and bone scintigraphy.

Authors:  Hui-Lin Yang; Tao Liu; Xi-Ming Wang; Yong Xu; Sheng-Ming Deng
Journal:  Eur Radiol       Date:  2011-09-02       Impact factor: 5.315

Review 6.  Acrometastases.

Authors:  Andreas F Mavrogenis; George Mimidis; Zinon T Kokkalis; Eirini-Sofia Karampi; Irene Karampela; Panayiotis J Papagelopoulos; Apostolos Armaganidis
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-09-08

Review 7.  Machine learning in quantitative PET: A review of attenuation correction and low-count image reconstruction methods.

Authors:  Tonghe Wang; Yang Lei; Yabo Fu; Walter J Curran; Tian Liu; Jonathon A Nye; Xiaofeng Yang
Journal:  Phys Med       Date:  2020-07-29       Impact factor: 2.685

Review 8.  PET and PET/CT imaging of skeletal metastases.

Authors:  Gary J R Cook
Journal:  Cancer Imaging       Date:  2010-07-19       Impact factor: 3.909

Review 9.  A systematic review of FDG-PET in breast cancer.

Authors:  S Escalona; J A Blasco; M M Reza; E Andradas; N Gómez
Journal:  Med Oncol       Date:  2009-03-11       Impact factor: 3.064

10.  The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer.

Authors:  Joo-Won Min; Sang-Won Um; Jae-Jun Yim; Chul-Gyu Yoo; Sung Koo Han; Young-Soo Shim; Young Whan Kim
Journal:  J Korean Med Sci       Date:  2009-04-21       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.